Adma Biologics Upgraded to Zacks #1 Strong Buy Following 6.1% Estimate Rise
Adma Biologics was upgraded to a Zacks Rank #1 Strong Buy after analysts raised its fiscal 2026 EPS estimate to $0.96, reflecting a 6.1% increase in consensus estimates over the past three months. This places the company in the top 5% of Zacks-covered stocks, signaling potential near-term upside.
1. Upgrade Details
Adma Biologics has been promoted to a Zacks Rank #1 (Strong Buy) after analysts lifted the fiscal 2026 EPS projection to $0.96, marking a 6.1% upward revision in the consensus estimate over the last three months.
2. Ranking Significance
Earning a Zacks Rank #1 places Adma in the top 5% of more than 4,000 covered stocks based solely on the magnitude and direction of earnings estimate revisions, a factor historically linked to above-market returns.
3. EPS Estimate Trends
Over the past quarter, analysts have consistently raised their forecasts for Adma Biologics, driving the consensus estimate higher despite the unchanged year-over-year EPS level of $0.96 for fiscal 2026.
4. Potential Impact
The upgrade underscores an improving earnings outlook that may attract institutional investors, potentially leading to increased buying activity and upward pressure on the stock in the near term.